N

Neuromuscular Research Center | Phoenix, AZ

Research site

(Unclaimed)

Location

4545 E Shea Boulevard Suite 175, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

Golodirsen

Casimersen

Edaravone

PF-06823859

ATB200

Pregabalin

RO7239361

SRP-4045

Fasudil

Miglustat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 17 total trials

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (RELIEVE)

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are...

Enrolling

Generalized Myasthenia Gravis

Drug: Remibrutinib (Blinded)

Drug: Remibrutinib (Open Label)

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM...

Enrolling

Myositis

Drug: PF-06823859

Drug: Placebo

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subject...

Active, not recruiting

Inclusion Body Myositis (IBM)

Drug: Ulviprubart (ABC008)

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Active, not recruiting

Amyotrophic Lateral Sclerosis

Drug: Fasudil (WP-0512)

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treat...

Active, not recruiting

Pompe Disease (Late-onset)

Biological: Cipaglucosidase Alfa

Drug: Miglustat